[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].

Tsuyoshi Muta, Toshihiro Miyamoto, Tomoaki Fujisaki, Yuju Ohno, Tomohiko Kamimura, Tomoko Henzan, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Tetsuya Eto, Yasushi Takamatsu, Takanori Teshima, Koichi Akashi, Blood Fukuoka Blood

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A high dose of melphalan followed by autologous stem cell transplantation (ASCT) is considered as the standard therapy for multiple myeloma. For induction therapy, 78 patients received conventional regimens (control group) and 32 patients received bortezomib-containing regimens (bortezomib group). We retrospectively compared the yield of harvested CD34+ cells between the two groups. In order to mobilize CD34+ cells, 83% of the control group and 63% of the bortezomib group received a high dose of cyclophosphamide followed by G-CSF, and 12% of the control group received a high dose of etoposide instead of cyclophosphamide. Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2×10(6)/kg, P=0.004). Regarding the patients mobilized by a high dose of cyclophosphamide followed by G-CSF, the rate of achieving CD34+ cells >2.0×10(6) cells/kg was similar. Bortezomib did not significantly affect the successful collection of at least CD34+ cells > 2.0×10(6) cells/kg after mobilization with a high dose of cyclophosphamide followed by G-CSF.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume54
Issue number1
Publication statusPublished - Jan 1 2013

Fingerprint

Multiple Myeloma
Granulocyte Colony-Stimulating Factor
Cyclophosphamide
Control Groups
Therapeutics
Melphalan
Bortezomib
Peripheral Blood Stem Cells
Stem Cell Transplantation
Etoposide

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma]. / Muta, Tsuyoshi; Miyamoto, Toshihiro; Fujisaki, Tomoaki; Ohno, Yuju; Kamimura, Tomohiko; Henzan, Tomoko; Kato, Koji; Takenaka, Katsuto; Iwasaki, Hiromi; Eto, Tetsuya; Takamatsu, Yasushi; Teshima, Takanori; Akashi, Koichi; Fukuoka Blood, Blood.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 54, No. 1, 01.01.2013, p. 109-116.

Research output: Contribution to journalArticle

Muta, T, Miyamoto, T, Fujisaki, T, Ohno, Y, Kamimura, T, Henzan, T, Kato, K, Takenaka, K, Iwasaki, H, Eto, T, Takamatsu, Y, Teshima, T, Akashi, K & Fukuoka Blood, B 2013, '[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 54, no. 1, pp. 109-116.
Muta, Tsuyoshi ; Miyamoto, Toshihiro ; Fujisaki, Tomoaki ; Ohno, Yuju ; Kamimura, Tomohiko ; Henzan, Tomoko ; Kato, Koji ; Takenaka, Katsuto ; Iwasaki, Hiromi ; Eto, Tetsuya ; Takamatsu, Yasushi ; Teshima, Takanori ; Akashi, Koichi ; Fukuoka Blood, Blood. / [Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma]. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2013 ; Vol. 54, No. 1. pp. 109-116.
@article{3c7e23b38ad54886a1ad95dd537b73d7,
title = "[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].",
abstract = "A high dose of melphalan followed by autologous stem cell transplantation (ASCT) is considered as the standard therapy for multiple myeloma. For induction therapy, 78 patients received conventional regimens (control group) and 32 patients received bortezomib-containing regimens (bortezomib group). We retrospectively compared the yield of harvested CD34+ cells between the two groups. In order to mobilize CD34+ cells, 83{\%} of the control group and 63{\%} of the bortezomib group received a high dose of cyclophosphamide followed by G-CSF, and 12{\%} of the control group received a high dose of etoposide instead of cyclophosphamide. Furthermore, 5{\%} of the control group and 38{\%} of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2×10(6)/kg, P=0.004). Regarding the patients mobilized by a high dose of cyclophosphamide followed by G-CSF, the rate of achieving CD34+ cells >2.0×10(6) cells/kg was similar. Bortezomib did not significantly affect the successful collection of at least CD34+ cells > 2.0×10(6) cells/kg after mobilization with a high dose of cyclophosphamide followed by G-CSF.",
author = "Tsuyoshi Muta and Toshihiro Miyamoto and Tomoaki Fujisaki and Yuju Ohno and Tomohiko Kamimura and Tomoko Henzan and Koji Kato and Katsuto Takenaka and Hiromi Iwasaki and Tetsuya Eto and Yasushi Takamatsu and Takanori Teshima and Koichi Akashi and {Fukuoka Blood}, Blood",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "54",
pages = "109--116",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "1",

}

TY - JOUR

T1 - [Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].

AU - Muta, Tsuyoshi

AU - Miyamoto, Toshihiro

AU - Fujisaki, Tomoaki

AU - Ohno, Yuju

AU - Kamimura, Tomohiko

AU - Henzan, Tomoko

AU - Kato, Koji

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Eto, Tetsuya

AU - Takamatsu, Yasushi

AU - Teshima, Takanori

AU - Akashi, Koichi

AU - Fukuoka Blood, Blood

PY - 2013/1/1

Y1 - 2013/1/1

N2 - A high dose of melphalan followed by autologous stem cell transplantation (ASCT) is considered as the standard therapy for multiple myeloma. For induction therapy, 78 patients received conventional regimens (control group) and 32 patients received bortezomib-containing regimens (bortezomib group). We retrospectively compared the yield of harvested CD34+ cells between the two groups. In order to mobilize CD34+ cells, 83% of the control group and 63% of the bortezomib group received a high dose of cyclophosphamide followed by G-CSF, and 12% of the control group received a high dose of etoposide instead of cyclophosphamide. Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2×10(6)/kg, P=0.004). Regarding the patients mobilized by a high dose of cyclophosphamide followed by G-CSF, the rate of achieving CD34+ cells >2.0×10(6) cells/kg was similar. Bortezomib did not significantly affect the successful collection of at least CD34+ cells > 2.0×10(6) cells/kg after mobilization with a high dose of cyclophosphamide followed by G-CSF.

AB - A high dose of melphalan followed by autologous stem cell transplantation (ASCT) is considered as the standard therapy for multiple myeloma. For induction therapy, 78 patients received conventional regimens (control group) and 32 patients received bortezomib-containing regimens (bortezomib group). We retrospectively compared the yield of harvested CD34+ cells between the two groups. In order to mobilize CD34+ cells, 83% of the control group and 63% of the bortezomib group received a high dose of cyclophosphamide followed by G-CSF, and 12% of the control group received a high dose of etoposide instead of cyclophosphamide. Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2×10(6)/kg, P=0.004). Regarding the patients mobilized by a high dose of cyclophosphamide followed by G-CSF, the rate of achieving CD34+ cells >2.0×10(6) cells/kg was similar. Bortezomib did not significantly affect the successful collection of at least CD34+ cells > 2.0×10(6) cells/kg after mobilization with a high dose of cyclophosphamide followed by G-CSF.

UR - http://www.scopus.com/inward/record.url?scp=84881480399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881480399&partnerID=8YFLogxK

M3 - Article

C2 - 23391654

AN - SCOPUS:84881480399

VL - 54

SP - 109

EP - 116

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 1

ER -